Cue Health

We are proud to partner with the National Coalition of STD Directors (NCSD) to provide Mpox Starter Kits (Cue Health Monitoring System and Cue Mpox (Monkeypox) Molecular Tests) to clinics in an effort to raise awareness about the importance of STD testing. Together, we aim to reduce the prevalence of sexually transmitted infections and improve overall public health outcomes. With the Centers for Disease Control and Prevention urging clinicians to be on the lookout for new cases of mpox, and if suspected, to test the patient even if they have had the vaccine or had mpox in the past, it is critical that healthcare providers have an accurate test they can trust, such as the Cue Mpox (Monkeypox) Molecular Test, which received EUA from the FDA, and allows healthcare professionals to accurately diagnose a case in 25 minutes, leading to timely care. Learn more about this partnership here: http://spr.ly/6045wUwQ1

The risks associated with COVID-19 infection are higher for immunocompromised individuals than the general public. If you, or someone you know, is immunocompromised or age 65+, please consider joining the ImmunoCARE study, which provides free molecular COVID-19 tests, telemedicine, and rapid home delivery of medication, if prescribed. ImmunoCARE is an innovative research project to study whether repeated at-home tests, on-demand telemedicine, and quick delivery of medication for those who test positive for COVID-19 can reduce COVID-19 severity in immunocompromised people. We are excited to partner with Scripps Research Digital Trials Center on this joint research project and hope you will consider joining us in helping to advance research on COVID-19 outcomes for immunocompromised individuals. Click here to see if you or someone you know is eligible to participate: http://spr.ly/6049Z0CPS

If you're experiencing symptoms, you can now gain peace of mind without making a trip to the doctor's office. Our molecular COVID-19 test allows you to test from home and receive results on your mobile phone in about 20 minutes. And with options for virtual care and prescription medication delivery, you can stay confident knowing fast, timely access to treatment is available if you ever need it. Discover how we've made it easy to get the care you need: http://spr.ly/6040ZpMA4

Point-of-care molecular results in 20 minutes. Whether you’re running a large healthcare network or an intimate family practice, we can help you streamline your ability to deliver value-based care with fast, highly accurate test results on demand. Discover how you can bring the unparalleled combination of accuracy, speed, and innovation of our Integrated Care Platform to your healthcare organization and patients: http://spr.ly/6047kW6GW

We recently hosted a booth at the San Diego Festival of Science & Engineering, supporting our nonprofit partner Generation STEAM. The Festival was a day-long STEAM event at which more than 130 local businesses provided interactive and hands-on science, technology, engineering, art, and math exhibits and activities for the entire community. Along with our R&D team, more than a dozen Cue Kindness volunteers gathered to lead a hands-on science experiment and share the technology behind our product with 1,000+ of the attendees. Check out our photos and learn more about Generation STEAM here: http://spr.ly/6040kwV3a #STEMeducation #STEM #STEAM #GenerationSTEAM #LoveStemSD

Today we reported our fourth quarter and full-year 2023 results, during which we reached a number of milestones: - Reported fourth quarter total revenue of $18.8 million. Full-year 2023 total revenue was $70.9 million - Submitted additional clinical samples and stability data for RSV to the FDA in support of de novo submission - Submitted additional clinical samples and gathering additional stability data for Flu A/B to the FDA in support of de novo submission - In late stage development of Herpes + Mpox Multiplex Molecular Test with plan to submit for EUA in 2Q24 - Executed cost reduction plans, resulting in cash savings of approximately $200 million on an annualized basis, while prioritizing near-term revenue generating opportunities - Reported cash and cash equivalents of $80.9 million as of December 31, 2023 "We made progress executing on our strategic priorities in 2023. We obtained two FDA authorizations including a de novo approval for our COVID-19 Molecular Test and an EUA for our Mpox Molecular Test, and made two de novo submissions for our RSV and Flu standalone molecular tests. We also drove significant development progress on our all-in-one Flu + COVID-19 + RSV test, our Herpes + Mpox multiplex test, and we expanded our Integrated Care Platform with a new suite of at-home diagnostics tests and treatments, all while streamlining our cost structure," said Ayub Khattak, Chairman and CEO of Cue. "We believe that these successes have positioned us well for 2024." Read more about this news here: http://spr.ly/6042ku8Le

Routine screening is one of the most effective ways to reduce your risk of #ColorectalCancer. According to the Centers for Disease Control and Prevention, an estimated 68% of deaths from colorectal cancer could be avoided if all eligible people got screened. Regular screening, beginning at age 45, is the key to preventing colorectal cancer and finding it early. This #ColorectalCancerAwarenessMonth, take proactive steps to protect your health with our Colon Cancer Screening test, which is recommended for adults aged 45 to 75, and allows you to screen yourself from the comfort and privacy of your home: http://spr.ly/6045ky2TX

Congratulations to Albert Perez, Beth Peralta, Chingyao Su, Felsie Joy Balico, Josh Bogikes, Eric Zhao, Lina Abdulnoor, and Hugo Pham for being recognized as our Cue Spotlight winners so far this year! Every month, People Managers from across our organization have the opportunity to nominate members of their team for Cue Spotlight, which is our company-wide recognition program for employees who truly exemplify our mission, vision, and values. • Albert Perez was nominated for winning together. • Beth Peralta was nominated for building boldly. • Felsie Joy Balico was nominated for excelling every day. • Chingyao Su was nominated for winning together. • Eric Zhao was nominated for excelling every day. • Josh Bogikes was nominated for winning together. • Lina Abdulnoor was nominated for excelling every day. • Hugo Pham was nominated for winning together. We appreciate your hard work and dedication to Cue! #WeAreCue

We're proud to support Generation STEAM’s efforts to empower the next generation of STEAM visionaries through education and exploration at this year's San Diego Festival of Science & Engineering. Stop by Booth 9 to meet with our team and learn about our mission to empower people to live their healthiest lives. Discover more about the event here: http://spr.ly/6046XrsM2 #STEM #STEAM #STEMeducation #GenerationSTEAM #LoveStemSD

According to the Centers for Disease Control and Prevention, 8.7 million people in the U.S. who have diabetes have not been diagnosed and do not know they have it. Using an at-home test, such as our Glucose + Insulin Test, allows you to monitor your blood glucose and insulin levels. This can help you understand your metabolic health and adapt your lifestyle and treatments to prevent or manage diabetes and other conditions. Discover our new Glucose + Insulin Test, which was selected by Forbes Health as one of the best at-home diabetes test kits of 2024: http://spr.ly/6048XH8NG